[
  {
    "ts": null,
    "headline": "Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks",
    "summary": "During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 97 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg",
    "url": "https://finnhub.io/api/news?id=11623b8c10db107d8317849f5fa52eb7f9c20dc5b7edb1dd8108c74126d88c58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755525694,
      "headline": "Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks",
      "id": 136502786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 97 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg",
      "url": "https://finnhub.io/api/news?id=11623b8c10db107d8317849f5fa52eb7f9c20dc5b7edb1dd8108c74126d88c58"
    }
  },
  {
    "ts": null,
    "headline": "Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers",
    "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers.",
    "url": "https://finnhub.io/api/news?id=20a099ab48ef5d684d3a48395efd1e197469e0bfef770b8f51452d6264dfc7c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755487992,
      "headline": "Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers",
      "id": 136409390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers.",
      "url": "https://finnhub.io/api/news?id=20a099ab48ef5d684d3a48395efd1e197469e0bfef770b8f51452d6264dfc7c8"
    }
  }
]